ASCO Genitourinary Symposium

Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC

February 20th 2025, 8:05pm

Article

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

February 20th 2025, 2:00pm

Article

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.

Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC

February 19th 2025, 10:00pm

Article

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

February 18th 2025, 10:00pm

Article

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.

Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma

February 18th 2025, 2:00pm

Article

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC

February 17th 2025, 8:00pm

Article

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment

February 17th 2025, 5:00pm

Video

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

Treatment Intensification Adoption Differences Across Prostate Cancer

February 16th 2025, 7:00pm

Video

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.

EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer

February 16th 2025, 3:00pm

Article

Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.

Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset

February 15th 2025, 10:52pm

Article

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.